J0693 – Injection, cefiderocol, 5 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ0693
- Long description
- Injection, cefiderocol, 5 mg
- Short description
- Inj., cefiderocol, 5 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Added
- January 1, 2021
- Last change
- October 1, 2021 – No change
- Termination date
- September 30, 2021
Frequently asked questions
What is HCPCS code J0693?
J0693 is a HCPCS Level II code for injection, cefiderocol, 5 mg. It was discontinued on September 30, 2021.
Does Medicare cover J0693?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J0675 – Injection, carboprost tromethamine, 0.1 mg
- J0681 – Injection, ceftobiprole medocaril sodium, 3 mg
- J0687 – Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
- J0688 – Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
- J0689 – Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg
- J0690 – Injection, cefazolin sodium, 500 mg
- J0691 – Injection, lefamulin, 1 mg
- J0692 – Injection, cefepime hydrochloride, 500 mg
- J0694 – Injection, cefoxitin sodium, 1 gm
- J0695 – Injection, ceftolozane 50 mg and tazobactam 25 mg
- J0696 – Injection, ceftriaxone sodium, per 250 mg
- J0697 – Injection, sterile cefuroxime sodium, per 750 mg
- J0698 – Injection, cefotaxime sodium, per gm
- J0699 – Injection, cefiderocol, 10 mg
- J0701 – Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
- J0702 – Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.